The Effects of the Endocrine System on Endometrial Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-10-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endometrial cancer usually begins in the endometrium, which is the tissue lining of the uterus. Endometrial cancer is the most commonly diagnosed gynaecological malignancy in Australia. It affects 1 in 80 Australian women and there are about 1400 new cases and 260 deaths from the disease every year. Most affected women are aged between 50 and 70 years. The purpose of this study is to investigate the possible role of the endocrine system in the regulation of human endometrial cancer. By looking at the laboratory results of people with endometrial cancer and also those without endometrial cancer we hope to gain a better understanding of how endometrial cancer develops and progresses. This may lead to the development of new, effective therapies for endometrial cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples

NCT01793545

Endometrial Cancer Gynecological Cancers

COMPLETED

Telephone Follow-up After Treatment for Endometrial Cancer

NCT01610375

Endometrial Cancer

COMPLETED NA

Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma

NCT05273099

Cancer of Endometrium

UNKNOWN

Risk Factors for Concurrent Endometrial Carcinoma in Patients With a Curettage Diagnosis of Endometrial Hyperplasia

NCT01273636

Endometrial Carcinoma

UNKNOWN

The Effect of Androgen Receptor Polymorphism on Endometrial Cancer

NCT05157373

Androgen Receptor Abnormal Endometrial Disorder

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Grade 2

Patients with Endometrial cancer of Grade 1 differentiation

No interventions assigned to this group

Benign

Patients without endometrial cancer

No interventions assigned to this group

Grade 1

Patients with Endometrial cancer of Grade 2 differentiation

No interventions assigned to this group

Grade 3

Patients with Endometrial cancer of Grade 3 differentiation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women aged 18 years or older
* having a hysterectomy for the treatment of endometrial cancer, fibroids, chronic pelvic pain or abnormal uterine bleeding
* have provided informed consent

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No